Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AAPL
6. HOOD
7. QCOM
8. ACN
9. AZN
10. ROIV

Go back to Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
(NASDAQ: PPCB) Delayed: 1.03 +0.02 (1.98%)
Previous Close $1.01    52 Week High $ 
Open $1.02    52 Week Low $ 
Day High $1.04    P/E N/A 
Day Low $0.99    EPS $ 
Volume 172,585       

(NASDAQ: PPCB) Delayed: 1.03 +0.02 (1.98%)
Previous Close $1.01    52 Week High $ 
Open $1.02    52 Week Low $ 
Day High $1.04    P/E N/A 
Day Low $0.99    EPS $ 
Volume 172,585